Alpha-9 Oncology
Julie Rousseau is currently the Associate Director of Translational Biology at Alpha-9 Oncology. Prior to this, Julie held positions at BC Cancer, Ecole nationale vétérinaire de Nantes, ESAV Institut Bonaparte, Inserm, and Pfizer. Julie's educational background includes a PhD in Molecular and Cellular Aspects of Biology from Nantes Université, as well as a Master's degree in Cellular Biology, Physiology, Biotechnologies, and Therapeutic Research. Throughout their career, Julie has focused on various research projects in molecular oncology, radiolabeled antibodies for therapy and imaging, bone marrow toxicity in internal radiotherapy, and the development of RNA interference molecules as therapeutic agents for rare bone diseases.
This person is not in any offices
Alpha-9 Oncology
Alpha-9 Oncology is a clinical stage, radiopharmaceutical company developing differentiated and highly targeted radiopharmaceuticals with the potential to meaningfully improve the treatment of people living with cancer. Applying proprietary technologies and deep-foundational expertise, Alpha-9 is on the forefront of engineering bespoke radiopharmaceuticals that are optimized to selectively deliver radiation to tumor sites while minimizing off-target effects. Alpha-9 is advancing a robust pipeline of novel radiopharmaceuticals with a systematic approach to molecule design that offers broad potential for expansion into several validated oncology targets. Alpha-9 was founded by researchers from the University of British Columbia and BC Cancer, with the goal of improving the lives of patients affected by metastatic cancers.